The Effects of the Telomerase Activator TA-65 on Insulin Resistance, Inflammation, and Metabolic Syndrome

Phase 1

Terminated

• Conditions: Insulin Resistance; Metabolic Syndrome
• Interventions: Dietary Supplement: Placebo; Dietary Supplement: TA-65

• Registration Number: NCT01753674
• Lead Sponsor: University of Connecticut

Brief Summary

Our hypothesis is that TA-65, a dietary supplement will help to reduce insulin resistance and plasma glucose in individuals classified with metabolic syndrome.

Detailed Description

This is double blind cross over randomized clinical trial. The supplement and placebo will be provided by TA Science, Inc. and prepared as described below. Subjects will be randomly allocated to consume either a daily serving of TA-65 (two capsules per day of 8 mg each) (please see attached label) or a placebo for 12 weeks. Randomization will be done in a sequential manner; the first subject will be allocated to supplement A and the next one to supplement B and so on. After a 3-week washout, they will be allocated to the alternate treatment for additional 12 weeks. Supplements (TA-65 or placebo) will be taken twice daily with a meal.

Participants will be advised not to change their diet or exercise protocols during the 27 week intervention. Volunteers will be required to provide a 5-day dietary record before starting the study, at the end of each supplement period (TA-65 or placebo) and at the end of the washout period. Subjects will have to fill an exercise questionnaire during the same times to ensure that there are no changes in physical activity. Participants will be asked to report to the department every 4 weeks for checking compliance on supplement intake and to assess weight and blood pressure.

Study Timeline

• Study First Submitted: 2012-12-17
• Study First Submitted QC: 2012-12-17
• Study First Posted: 2012-12-20
• Study Start: 2013-01
• Primary Completion: 2014-06
• Study Completion: 2014-06
• Status Verified: 2015-05
• Last Update Submitted: 2015-05-27
• Last Update Posted: 2015-05-28

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 13

Inclusion Criteria

The inclusion criteria are:

men and women (40-70 y) with metabolic syndrome which means having at least 3 of the following characteristics:

• Blood pressure > 130/85 mm Hg
• plasma glucose > 100 mg/dL
• plasma triglycerides > 150 mg/dL
• HDL cholesterol < 40 mg/dL (men) and < 50 mg/dL (women)
• waist circumference >102 cm (men) and ≥ 88 cm (women)
• Women of childbearing age should be using contraception

Exclusion Criteria

Exclusion criteria will be

• self-reported diabetes mellitus
• coronary heart disease
• triglycerides greater than 400 mg/dL
• Fasting glucose greater than 126 mg/dL
• Blood pressure greater than 140/100 mmg Hg
• history of stroke
• Use of alcohol at an elevated rate (more than two drinks per day)
• Renal problems
• liver disease
• cancer
• pregnancy and lactation
• severe infectious diseases
• autoimmune disease currently under treatment
• current hormone therapy
• previous treatment with TA-65.
• Intake of glucose-lowering prescriptions
• Use of immunosuppressants, lithium or supplements such as Sulphonylureas (Glucotrol, Amaryl), Thiazolidinedione (Avandia, ACTOS,), Meglitinides (Prandin, Starlix), Biguanides (Metformin), Alpha-glucosidase inhibitors (Precose, Glyset), dipeptidyl peptidase (DPP)-4 inhibitors (Januvia, Onglyza)
• high dose chromium or cinnamon supplements
• Consistent intake of vitamin, mineral, or multivitamin supplements prior to recruitment may be admitted into the study if they plan on maintaining their current supplement program.

However, subjects may not participate if they begin taking a new supplement during the 27-wk study period.

-Subjects will also be asked to refrain from taking any additional supplements, including fish oil, herb and concentrated antioxidant sources.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Placebo will be provided to volunteers for 12 weeks, 2 pills per day of 8 mg each.
TA-65	TA-65	TA-65 will be provided to volunteers for 12 weeks, two pills per day of 8 mg each

Primary Outcome Measures

Name	Time	Method
Plasma insulin levels	27 weeks	The supplement is anticipated to decrease insulin resistance in individuals with metabolic syndrome. The investigators will measure plasma insulin and plasma glucose as outcomes measures

Secondary Outcome Measures

Name	Time	Method
plasma HDL cholesterol	27 weeks	It is expected that the TA-65 supplement will increase plasma HDL, another characteristic of metabolic syndrome

Trial Locations

Locations (1)

University of Connecticut; 🇺🇸 Storrs, Connecticut, United States